作者: C. Messiou , N. Tunariu , J.M. Winfield , M.D. Blackledge , D.-M. Koh
DOI: 10.1016/J.CRAD.2021.04.001
关键词:
摘要: Whole-body magnetic resonance imaging (MRI) is now a crucial tool for the assessment of extent systemic malignant bone disease and response to treatment, forms part national international recommendations patients with myeloma or metastatic prostate cancer. Recent developments in scanners have enabled acquisition good-quality whole-body MRI data within 45 minutes on modern systems from all main manufacturers. This provides complimentary morphological functional imaging; however, lack prior experience times required can act as barrier adoption busy radiology departments. article aims tackle former by reviewing indications providing guidance technical delivery clinical interpretation disease.